Biogen Inc

NASDAQ:BIIB   3:59:57 PM EDT
333.94
+2.01 (+0.61%)
4:34:59 PM EDT: $333.66 -0.28 (-0.08%)
Products

FDA Approves Updated Aduhelm™ Prescribing Information To Emphasize Population Studied In Clinical Trials

Published: 07/08/2021 11:46 GMT
Biogen Inc (BIIB) - FDA Approves Updated Aduhelm™ Prescribing Information to Emphasize Population Studied in Clinical Trials.
Biogen Inc - Aduhelm Should Be Initiated in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease Or Mild Alzheimer's Dementia.
Biogen Inc - Update Clarifies Indication by Emphasizing Information About Disease Stages Studied in Aduhelm Clinical Trials.